Ainos, Inc. (NASDAQ: AIMD, NASDAQ: AIMDW) has provided additional details on its VELDONA® License Agreement, originally announced Sept. 24, 2026, including payment terms and a breakdown of potential revenue streams.

The company expects to receive an initial license fee of $600,000 within 15 business days after applicable payment conditions are met, with no dependency on future clinical trial outcomes or marketing approval.

Under the agreement, a pharmaceutical development partner will fund and execute clinical and regulatory activities for two initial licensed indications: Sjögren's disease and thrombocytopenia. Ainos retains 25% of applicable net sublicensing revenue, which may include upfront payments, option fees, milestones and royalties.

Additional financial provisions include a one-time first-sublicense fee payable within 30 days after the first third-party sublicense takes effect, a pathway for up to 15 additional VELDONA indications under separate agreements, and potential product supply revenue under separately negotiated arrangements.

Ainos described a potential $10 million framework encompassing the initial license fee, conditional additional-indication consideration and the first-sublicense fee, while noting that sublicensing revenue participation and supply revenue fall outside that figure. The company stated that $10 million is not a ceiling on its total economic participation and that no guaranteed revenue has been established.

VELDONA is a low-dose oral interferon alpha platform administered as a lozenge. Ainos disclosed a clinical history spanning approximately four decades and 68 studies across 16 disease indications, with nearly 6,000 participants enrolled.

Ainos retains ownership of its existing VELDONA platform and background intellectual property, subject to rights granted under the agreement.

Eddy Tsai, Chairman, President and Chief Executive Officer, said the partnership structure allows the company to "keep Ainos focused on Chemical Intelligence," adding that the objective is to "measure progress through delivery, payments received, development milestones and execution in our core AI business."

The company stated that Chemical Intelligence and its AI Nose technology remain its primary strategic focus.